Por favor, use este identificador para citar o enlazar a este item:
Compartir / Impacto:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
|Autor:||Sanz-Gallego, Irene; Rodríguez de Rivera, Francisco J.; Pulido, Irene; Torres Alemán, Ignacio ; Arpa, Javier|
|Fecha de publicación:||2-oct-2014|
|Citación:||Cerebellum & Ataxias 1(1): 13 (2014)|
The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients.|
[Results] A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 completed our study. They were 8 females and 18 males, 28 to 74 years of age (average ± SD: 49.3 ± 14.1). Patients were treated with IGF-1 therapy with a dosage of 50 μg/kg twice a day for 12 months. The efficacy of this therapy was assessed by change from baseline on the scale for the assessment and rating of ataxia (SARA). Ten patients, consecutively selected, continued their assigned dosages in a second year open-label extension trial. A statistically significant improvement in SARA scores was observed for patients with SCA3, patients with SCA7 and all patients grouped together after the first year of IGF-1 therapy, while a stabilization of the disease was confirmed during the second year (extension study). The single patient with SCA6 showed 3 improvement points in SARA score after 3 four-month periods of IGF-1 therapy when compared with baseline measurements. Our data indicate that IGF-1 is safe and well tolerated in general.
[Conclusions] Our data, in comparison with results from previous cohorts, indicate a trend for IGF-1 treatment to stabilize the disease progression for patients with SCA, indicating that IGF-1 therapy is able to decrease the progressivity of ADCA.
|Versión del editor:||http://dx.doi.org/10.1186/s40673-014-0013-8|
|Aparece en las colecciones:||(IC) Artículos|
Ficheros en este ítem:
|40673_2014_Article_13.pdf||1,02 MB||Adobe PDF|